Medpace (MEDP)
(Delayed Data from NSDQ)
$400.21 USD
+4.28 (1.08%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $402.75 +2.54 (0.63%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MEDP 400.21 +4.28(1.08%)
Will MEDP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MEDP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MEDP
Zacks Industry Outlook Highlights Elevance Health Medpace and Doximity
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
MEDP: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Medical Services Industry Stocks to Buy as Nursing Market Booms
Medpace (MEDP) Beats Q1 Earnings Estimates
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
Other News for MEDP
MEDP Crosses Above Average Analyst Target
Medpace price target raised by $11 at Guggenheim, here's why
Medpace price target raised by $8 at Baird, here's why
Medpace Holdings Inc (MEDP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...
Medpace raised to Buy at Jefferies after Q1 earnings beat